-
Mashup Score: 0Treating DCIS: To Escalate or De-escalate? - 14 hour(s) ago
There is much debate about the necessity of treating women with ductal carcinoma in situ (DCIS) with surgery or radiotherapy. 1,2 It is disconcerting to many that patients with DCIS are treated in the same way as are women with early-stage invasive breast cancer. Many patients with DCIS have bilateral mastectomies. 2 Much effort is being expended to identify women at sufficiently low risk who might avoid surgery and/or radiotherapy. 3-9 In a recent paper from the UK, Mannu et al followed women with DCIS
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1AI Model May Help Predict Treatment Responses, Select Most Effective Cancer Therapies in Patients With Cancer - 16 hour(s) ago
Can a novel artificial intelligence (AI) model accurately predict how patients with cancer will respond to certain cancer drugs? A recent study investigated.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Advanced-Stage Classical Hodgkin Lymphoma - 1 day(s) ago
Classical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following fron…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Sophia McKinley, MD, EdM, on Cutaneous Melanoma: Outcomes With Adjuvant Immunotherapy - 1 day(s) ago
Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies the risk factors associated with overall survival and treatment failure (Abstract 60). Jenny H. Chang, MD, of the Cleveland Clinic, discusses the current surgical and radiologic treatment paradigm for patients with stage III Merkel cell carcinoma and the potential for neoadjuvant immunotherapy to help manage the
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
In a prospective cohort study, among patients hospitalized due to COVID-19 infection, those receiving cancer treatment had a higher rate of in-hospital mortality vs those without a cancer diagnosis.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved - 1 day(s) ago
Recently, the FDA approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative detection of cancerous tissue within the resection cavity following removal o…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Researchers have investigated whether spatial tissue analysis may help predict early posttreatment relapse and illuminate new potential therapies in patients with high-grade serous ovarian carcinoma. …
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Researchers may have uncovered how the long-term daily use of aspirin may help prevent the development and progression of colorectal cancer, according to a recent study.
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Sophia McKinley, MD, EdM, on Cutaneous Melanoma: Outcomes With Adjuvant Immunotherapy - 2 day(s) ago
Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies the risk factors associated with overall survival and treatment failure (Abstract 60). Jenny H. Chang, MD, of the Cleveland Clinic, discusses the current surgical and radiologic treatment paradigm for patients with stage III Merkel cell carcinoma and the potential for neoadjuvant immunotherapy to help manage the
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
The FDA approved lutetium Lu-177 dotatate (Lutathera) for pediatric patients aged 12 years and older with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)—includi…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Steven A. Narod, MD, on Treating DCIS: To Escalate or De-escalate? https://t.co/kFROr8dQ9h #bcsm #breastcancer #DCIS #oncology @WCHospital @UofT_dlsph @WCHResearch